ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives $7.33 Average Price Target from Brokerages

ProQR Therapeutics N.V. (NASDAQ:PRQR) has received an average rating of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $7.3333.

A number of equities analysts have commented on the company. JonesTrading decreased their target price on ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, June 26th. Citigroup reiterated a “market outperform” rating on shares of ProQR Therapeutics in a research report on Wednesday, May 27th. Chardan Capital cut their price target on ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, June 26th. Weiss Ratings lowered ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 23rd. Finally, Wall Street Zen downgraded ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th.

Insider Buying and Selling at ProQR Therapeutics

In other news, CEO Boer Daniel Anton De acquired 150,000 shares of the business’s stock in a transaction that occurred on Thursday, July 9th. The shares were purchased at an average cost of $1.74 per share, for a total transaction of $261,000.00. Following the transaction, the chief executive officer directly owned 300,000 shares in the company, valued at $522,000. This trade represents a 100.00% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bart Filius bought 150,000 shares of ProQR Therapeutics stock in a transaction on Friday, July 17th. The shares were purchased at an average cost of $1.72 per share, with a total value of $258,000.00. Following the completion of the purchase, the director directly owned 300,000 shares in the company, valued at $516,000. This trade represents a 100.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have bought 600,000 shares of company stock valued at $988,500. Corporate insiders own 8.40% of the company’s stock.

Institutional Investors Weigh In On ProQR Therapeutics

Hedge funds have recently made changes to their positions in the business. Osaic Holdings Inc. grew its holdings in ProQR Therapeutics by 59.6% in the 2nd quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 4,500 shares in the last quarter. Persistent Asset Partners Ltd raised its stake in ProQR Therapeutics by 24.5% during the 4th quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company’s stock valued at $91,000 after acquiring an additional 8,874 shares in the last quarter. Diadema Partners LP raised its stake in ProQR Therapeutics by 6.2% during the 4th quarter. Diadema Partners LP now owns 167,532 shares of the biopharmaceutical company’s stock valued at $338,000 after acquiring an additional 9,838 shares in the last quarter. Bank of America Corp DE boosted its position in ProQR Therapeutics by 6.4% during the 1st quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company’s stock worth $300,000 after acquiring an additional 11,186 shares during the period. Finally, Raymond James Financial Inc. boosted its position in ProQR Therapeutics by 15.2% during the 3rd quarter. Raymond James Financial Inc. now owns 110,270 shares of the biopharmaceutical company’s stock worth $235,000 after acquiring an additional 14,549 shares during the period. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Stock Performance

Shares of NASDAQ:PRQR opened at $1.88 on Tuesday. The company’s fifty day moving average is $1.70 and its two-hundred day moving average is $1.65. ProQR Therapeutics has a 1-year low of $1.33 and a 1-year high of $3.10. The stock has a market capitalization of $197.56 million, a price-to-earnings ratio of -3.75 and a beta of 0.07.

ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, meeting the consensus estimate of ($0.15). ProQR Therapeutics had a negative net margin of 331.33% and a negative return on equity of 84.87%. The business had revenue of $2.35 million during the quarter, compared to analyst estimates of $5.19 million. Sell-side analysts expect that ProQR Therapeutics will post -0.52 EPS for the current fiscal year.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.